Abstract. There is evidence that aspirin and other non-steroidal anti-inflammatory drugs may be protective agents against cancer in the gastrointestinal tract. These effects are particularly well documented for the colon and rectum. Some epidemiological and experimental studies have suggested that aspirin could also be a chemopreventive agent against breast cancer. We investigated the effects of the aspirin metabolite, salicylate (SA), on 7,12-dimethylbenz[a]anthracene (DMBA)-DNA adduct formation as well as on the expression of the enzymes involved in the carcinogen bioactivation pathway, in particular cytochrome P450 1A (CYP1A) and cyclooxygenases (COX-1 and COX-2). The effects of the test drug were examined in both the human mammary carcinoma cell line, MCF-7, and mammary cells derived from DMBA-induced rat mammary tumours (RMTCs). In this study, we also reported the effects of SA on cell growth and viability in breast cancer cells (BCCs). The results demonstrated that DMBA-DNA adduct formation in both cancer cell lines was inhibited by SA at concentrations of ≥ 2.5 mM. CYP1A was undetectable in RMTCs while CYP1A induction by ß-naphthoflavone in MCF-7 cells was significantly inhibited by SA in a concentration-dependent manner. Aspirin did not affect COX-1 expression in either of the BCCs. COX-2 was not detected in MCF-7 cells, but its expression in RMTCs was inhibited by SA treatment, which also significantly reduced BCC growth, but failed to cause cell death by necrosis or apoptosis. These data suggest that inhibition of DMBA-DNA adduct formation may contribute to aspirin breast cancer chemopreventive action and indicate that this drug can act in the first stage of carcinogenesis.
Introduction
The high prevalence of breast cancer provides a strong rationale for identifying new compounds, both natural and synthetic, for use as cancer chemopreventive agents. There is evidence that a variety of chemicals can inhibit, delay, and/or reverse cancer induced by either environmental insults and/or life-style. Non-steroidal anti-inflammatory drugs (NSAIDs) are among the molecules that have emerged as promising candidates for breast cancer prevention (1) . Their chemopreventive action in breast cancer has been suggested in several epidemiological (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) and experimental studies (12) (13) (14) (15) (16) (17) (18) . Different mechanisms have been proposed to explain the antitumourigenic action of NSAIDs, including inhibition of cell proliferation and angiogenesis, stimulation and promotion of apoptosis, and inhibition of cyclooxygenase-2 (COX-2)-mediated inflammation, immunosuppression and enhanced invasiveness (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) . Many chemical agents with antitumourigenic properties can modify the mutagenic and carcinogenic effects of environmental carcinogens such as 7,12-dimethylbenz[a]anthracene (DMBA). For the initiation stage of carcinogen-induced tumourigenesis, a metabolic activation of the carcinogen to reactive metabolites that bind covalently to DNA is required (32) . In particular, DMBA is biotransformed by cytochrome P450s (CYPs) to electrophilic dihydrodiolepoxides leading to DNA modifications, mutagenicity, and carcinogenicity. This may proceed through a primary metabolic step carried out by hepatic metabolism, or through complete metabolic activation in the breast in situ, or a combination of both processes (33) . It has been reported that many xenobiotic metabolizing enzymes are expressed in the breast and that cyclooxygenase (COX), also referred to as prostaglandin H-synthase (PGHS), may play an important role in carcinogen bioactivation in this or other extrahepatic tissues (34) . A variety of chemopreventive agents have been shown to inhibit the in vivo formation of DMBA-induced DNA adducts in rodent mammary cells (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) .
The main objective of this study was to investigate the effects of the aspirin metabolite, salycilate (SA), on DMBA-DNA adduct formation as well as on the expression of the enzymes involved in the carcinogen bioactivation pathway, in particular CYPs and COX. For this purpose we used the human breast cancer cell line, MCF-7, because it derives from the mammary epithelium, the target tissue of DMBA, and because carcinogen activation has been well characterized in these cells (45, 46) . Furthermore, recent studies have demonstrated that MCF-7 cells are similar to normal human mammary epithelial cells with regard to expression and activity of CYP1A1, the principal CYP isoform involved in DMBA bioactivation in the liver (47) (48) (49) . Since a recent in vivo study has shown that SA inhibited DMBA-induced rat mammary carcinogenesis (50), the same goal was pursued in mammary cells derived from DMBA-induced rat mammary carcinomas (RMTCs). In this work, we also reported the effects of SA on cell growth and viability in breast cancer cells (BCCs).
Materials and methods
DMBA tumour induction, mammary tumour cell separation and culture. Mammary tumours were induced in 50-day-old outbred female Sprague-Dawley rats (Charles River, Calco, Lecco, Italy) by three intragastric intubation of 1 ml DMBA (10 mg/ml in olive oil). All animal procedures were carried out in compliance with the EC Directive 86/609/EEC and with the Italian law regulating experiments on animals. When the tumour mean diameter was approximately 1.5 cm, animals were sacrificed by carotid bleeding under CO 2 anaesthesia and tumour tissue was isolated under aseptic conditions to obtain primary cultures of RMTCs (51, 52) . Tissue was freed from necrotic areas and minced with a scalpel in RPMI-1640 medium supplemented with 5% antibiotics. The minced tissue was resuspended in the same medium containing 0.3% collagenase and incubated for 90 min at 37˚C. Afterwards, the suspension was passed through an 80-mesh sieve to remove undigested masses, washed three times with RPMI-1640 (Sigma-Aldrich, Milano, Italy) supplemented with 10% foetal bovine serum (FBS, Sigma-Aldrich) and plated into culture dishes for a 90-min period. During this time, many stromal elements adhered to the plastic surfaces, while epithelial and blood cells remained in the supernatants. Remaining stromal and blood cells were then removed and passed through a 270-mesh sieve, while the ductal fragments, containing most of the epithelial cells, were trapped on the sieve and then removed from it by reverse flushing after washing. The tumour cells thus prepared were resuspended in RPMI-1640 supplemented with 10% FBS, 1% glutamine 200 mM, 1.6% antibiotics (5000 units penicillin, 5 mg/ml streptomycin) and hormones (0.5 μg/ml insulin, 1 μg/ml prolactin, 1 μg/ml corticosterone) and plated in a 75-cm 2 T-flask. Cells were grown until confluence at 37˚C in an atmosphere of 95% air, 5% CO 2 .
The percentage of epithelial cells in culture was quantized using immunohistochemical and flow cytometric analysis. Immunohistochemical examination revealed positivity for keratin (epithelial cell membrane antigen), and negativity for vimentin (marker of mesenchymal cells). Flow cytometry revealed positivity for keratin, negativity for muscle-specific actin and CD45 (leukocyte common antigen).
MCF-7 cell culture. MCF-7 cells were routinely cultured in RPMI-1640 medium supplemented with 1% glutamine 200 mM, 1.6% antibiotics (5000 units penicillin, 5 mg/ml streptomycin) and 10% FBS in an atmosphere of 95% air, 5% CO 2 at 37˚C. 3 H]DMBA was cleaned by evaporating the toluene solvent using a nitrogen stream, redissolving the residue in 3 ml of hexane, and extracting the hexane phase 10 times using 2 ml of 0.25 M NaOH in 40% ethanol (53) . Cells were washed twice with cold 0.1 M phosphate-buffered saline solution (PBS), pH 7.4, trypsinized and pelleted. Nuclei were isolated by incubating the cells for 10 min on ice in 10 mM Tris-HCl (pH 7.5), with 320 mM sucrose, 5.0 mM magnesium chloride and 1% Triton X-100. The nuclei were pelleted by centrifugation at 800 x g for 10 min at 4˚C, and this digestion was repeated once (44) . Nuclei were then lysed with 10 mM Tris-HCl, 400 mM NaCl and 2.0 mM Na 2 EDTA, pH 8.2, followed by treatment overnight at 37˚C with 0.2 ml of 10% sodium dodecyl sulphate (SDS) and 0.5 ml of proteinase K solution (1 mg proteinase K in 1% SDS and 2 mM Na 2 EDTA). After digestion was complete, 1 ml of saturated NaCl (approximately 6 M) was added to each sample and shaken vigorously for 15 sec, followed by centrifugation at 1500 x g for 15 min at 4˚C. Genomic DNA was then isolated from supernatant by repeated ethanol precipitation as described by Miller et al (54) . Isolated DNA exhibited a 260/280 ratio of >1.9. The amount of DNA was measured by spectrophotometry and radioactivity bound to DNA was quantified by liquid scintillation counting in a Packard counter. Results were expressed as fmoles [ 3 H]DMBA/mg DNA.
Evaluation of SA effects on CYP1A, COX-1 and COX-2 expression and induction by Western blot analysis
Sample preparation. CYP1A: to induce CYP1A expression, cells were incubated for 24 h in the presence of medium containing 0.1% dimethyl sulfoxide (DMSO) as vehicle or in the presence of 10 μM ß-naphthoflavone (ß-NF) or 10 μM DMBA, dissolved in DMSO, alone or in association with SA 2.5, 3.0 and 5.0 mM. Afterwards, microsomes were isolated as follows: detached cells were washed with PBS and homogenized by sonication at 4˚C in 20 mM Tris-HCl, 1.15% KCl, 1.0 mM EDTA, 1.0 mM phenylmethylsulfonylfluoride (PMSF), 2.0 μg/ml aprotinin, and 2.0 μg/ml leupeptin. The homogenates were centrifuged for 30 min at 10,000 x g at 4˚C and supernatants were subjected to further centrifugation at 100,000 x g for 60 min at 4˚C. The resulting microsomal pellets were resuspended in 10 mM Tris-acetate, 1.0 mM EDTA, and 20% glycerol and sonicated in order to obtain a homogenous membrane suspension. Protein concentration was determined for each sample using the Lowry assay (55). COX-1: cells were exposed for 24 h to 0.1% DMSO as vehicle, and 1 μM DMBA dissolved in DMSO, alone or in association with SA 2.0, 2.5, 3.0 or 5.0 mM. After trypsinization and washing in cold PBS, whole-cell lysates were prepared by incubating cells with lysis buffer [50 mM HEPES, 250 mM NaCl, 10% glycerol, 1.0% Triton X-100, 1.5 mM MgCl 2 , 1.0 mM PMSF, 1.0 mM EGTA, 2.0 mM Na 3 VO 4 , 10 μg/μl aprotinin and 10 μg/μl leupeptin] on ice for 1 h as described by Pham et al (56) . Protein estimation was performed using the Bradford method (57).
COX-2: cells were exposed to 0.1% DMSO, and 1 μM DMBA dissolved in DMSO, alone or in the presence of SA 2.5 or 5.0 mM for 24 h and lysed on ice for 30 min in 70 μl/ 10,000,000 cells of immunoprecipitation lysis buffer (20 mM HEPES pH 7.9, 0.35 M NaCl, 1.0 mM MgCl 2 , 0.5 mM EDTA, 0.1 mM EGTA, 20% glycerol, 1% NP-40) containing 1.6 mg/ml aprotinin, 5.0 mM dithiothreitol (DTT), and 3.0 mM PMSF. Lysates were collected and centrifuged at 12,000 x g for 15 min at 4˚C. Supernatant protein content was estimated by the Bradford assay (57). Aliquots of cellular lysate (100 μg of proteins) were incubated overnight at 4˚C with a COX-2-specific primary antibody in 50 μl of RIPA's buffer (20 mM Tris-HCl, 150 mM NaCl, 10 μl/ml NP-40) containing 1.6 mg/ ml aprotinin, 5.0 mM DTT, 3.0 mM PMSF and 5.0 mM EDTA. Protein A-Sepharose slurry (15 μl) (Sigma-Aldrich) was added to the antibody-treated lysates and incubated for 2 h at 4˚C. Protein A-Sepharose beads were collected and washed 2 times with RIPA's buffer.
Western blotting. Samples and immunoprecipitates that contained 100 μg of proteins were mixed with Laemmli sample buffer and boiled for 5 min before being loaded into 10% (COX-1 and COX-2) or 12% (CYP1A1/1A2) bis-acrylamide gels and separated by SDS polyacrylamide gel electrophoresis. Separated proteins were electrophoretically transferred from gels to nitrocellulose membranes. Blots were blocked for 1 h in a PBS-0.1% Tween-20 and 5% low-fat milk. Membranes were probed overnight at 4˚C with specific primary antibodies: polyclonal rabbit antibody specific for COX-1 (H-62, Santa Cruz Biotechnology, final dilution 1:500), polyclonal rabbit antibody specific for COX-2 (Cayman Chemical, final dilution 1:200) and polyclonal goat antibody specific for CYP1A1/1A2 (Oxford Biomedical Research, final dilution 1:100). Immunodetection was performed using a chemiluminescence (ECL) kit (Amersham Pharmacia Biotech), according to the manufacturer's instructions. Immunopositive bands were captured by the Kodak Image Station 440CF system and their optical density was analysed using Kodak 1D image analysis software. 4 cells/ well in 96-well plates. After 48 h, they were washed twice and incubated for 24 h in 1% FBS-containing medium in the presence of SA at the concentrations reported above. Cells were then labelled overnight with 5.0 μCi/100 μl of [methyl-3 H]-thymidine/well and DNA synthesis was measured as described by Novelli et al (59) . Results were expressed as average of cpm taken up by each group of treatment.
Measurement of cell viability. Cell viability was assessed using the following methods: propidium iodide (PI, Sigma-Aldrich) staining assay, lactate dehydrogenase (LDH, Sigma-Aldrich) release, Hoechst-33342 (Sigma-Aldrich) staining assay and DNA analysis.
The PI staining assay is based on necrosis-related cell membrane permeation to IP. Cells were seeded at 30,000 cells/ well on 24-well plates. After 48 h of culture, cells were washed with PBS and incubated for 24 h in 1.0% FBS-containing medium in the presence of SA at concentrations of 0, 2.0, 2.5, 3.0 and 5.0 mM. Next, the samples were incubated for 15 min at room temperature in the dark with 1 μg/100,000 cells PI. After incubation, adherent cells were detached using trypsin (0.5% trypsin/0.1% EDTA in PBS). Detached cells were harvested by centrifugation at 80 x g for 10 min and resuspended to 0.2x10 6 cells/ml in serum-free medium. Cells were applied to glass slides (5x10 4 cells/slide) by cytocentrifugation at 20 x g for 5 min (Cytospin cytocentrifuge, Shandon, Inc., Pittsburg, PA). After fixing with ethanol/diethyl ether 1:1 for 10 min at room temperature, all slides were sealed with glycerol and analyzed using a fluorescent microscope Leica PMIRE-2 with a UV filter and a x40 oil-immersion lens (Leica Microsystem Wetzlar GmbH, Wetzlar, Germany).
The leakage of LDH into the culture medium after exposure of cells to the different concentrations of SA for 24 h was measured using a colorimetric method (60) . Briefly, 0.1 ml samples were mixed with 0.1 ml of LDH substrate mixture (5.4x10 The Hoechst-33342 staining assay was utilized in order to evaluate changes in cell nuclear morphology after exposure to SA. Cells were cultured, treated and applied to glass slides as described for IP staining. After fixing with ethanol/diethyl ether 1:1 for 10 min at room temperature, the cells were washed with PBS and incubated for 30 min at room temperature in the dark in 0.8 μM Hoechst-33342/PBS solution. All slides were washed three times with 0.1 M PBS and sealed with glycerol. Nuclear morphology was examined using a fluorescent microscope Leica PMIRE-2 as described for the IP test. Nuclei are considered to have the normal phenotype when glowing bright and homogeneously. Apoptotic nuclei can be identified by condensed chromatin gathering at the periphery of the nuclear membrane or a total fragmented morphology of nuclear bodies.
To evaluate SA cell toxicity, the DNA fragmentation assay was also performed. In brief, cells, cultured and treated as previously described were incubated in 30 μl/1x10 6 cell lysis buffer containing 10 mM EDTA, 0.5% SDS and 0.5 mg/ ml proteinase K in 50 mM Tris-HCl (pH 8.0) for 1 h at 50˚C. The reaction was stopped in ice and each sample was incubated with 10 μg/ml RNAase for 1h at 50˚C. The samples were further incubated for 10 min at 70˚C to inactivate both proteinase K and RNAase. After addition of 0.3 M ammonium acetate, DNA was extracted using cold ethanol, pelleted and resuspended in sterile water. The amount and the pureness of DNA were determined by spectrophotometry. The degree of fragmentation was analyzed using 2% agarose gel electrophoresis and ethidium bromide staining (61).
Statistical analyses. Data were expressed as means ± SD and subjected to one-way ANOVA followed by the Newman-Keuls test to determine the statistical significance of the differences between the experimental groups. A p<0.05 was considered significant. (Tables I and II) . 
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SA-mediated modulation of CYP1A, COX-1 and COX-2.
CYP1A: immunoblots carried out in microsomal fractions with the appropriate antibody to assess the constitutive expression and induction of CYP1A in each cell type showed a very low protein expression in untreated MCF-7 cells. Following treatment with 10 μM DMBA, there was a slight and not significant increase in CYP1A1/1A2 immunoreactive protein.
In contrast, protein expression was more notably enhanced (+17%) in microsomes from 10 μM ß-NF treated cells; this phenomenon was significantly inhibited by SA in a concentration-dependent manner (Fig. 1) . CYP1A1/1A2 was seemingly neither constitutively expressed nor induced in RMTCs under the same conditions (data not shown). COX-1 and COX-2: immunoblotting results (Figs. 2 and 3 ) indicated that blots for COX-1 protein from MCF-7 cells and RMTCs were similar. COX-1 expression was little affected by DMBA alone and the concurrent exposure to SA did not result in appreciable changes in the enzyme expression, irrespective of the cell source. COX-2 was undetectable in MCF-7 cells (data not shown), but clearly detectable in RMTCs. COX-2 expression was seemingly not modified by DMBA alone, while cells exposed to both DMBA and SA displayed a significant decrease in protein signal (Fig. 4) .
Effects of SA on breast cancer proliferation. MCF-7 cells and
RMTCs were incubated for 24 h with SA at concentrations ranging from 2.0 to 5.0 mM. As revealed by the MTT assay, SA significantly decreased the number of both types of BCC at concentrations of ≥2.0 mM (Figs. 5 and 6). [ 3 H]-thymidine incorporation studies showed that, after 24-h incubation, the inhibition of DNA replication by SA was significant at concentrations of ≥2.5 mM (Figs. 7 and 8) .
Effects of SA on breast cancer cell viability. The evaluation of SA cell toxicity was performed using different assays to discriminate between necrosis and apoptosis. As assessed by the PI assay (Fig. 9) , neither of the BCCs exhibited any morphological change after the exposure for 24 h to SA at the lowest (2.0 mM) or highest (5.0 mM) tested concentrations.
Likewise, cell damage evaluated in terms of LDH release was not induced by SA treatment (Fig. 10) . We used Hoechst 33342 staining and DNA ladder assay to study the effects of SA on apoptosis. No apoptotic bodies containing nuclear fragments were found in BCCs exposed to SA 2.0 or 5.0 mM for 24 h (Fig. 11) . Gel electrophoresis of DNA from BCCs treated with increasing concentrations of SA for 24 h revealed a 'ladder' pattern that indicated no DNA degradation (Figs. 12 and 13) .
Discussion
The present study shows that treatment of mammary cancer cells for 24 h with different concentrations of SA inhibits DMBA-DNA adduct formation, a phenomenon which is generally accepted as a critical step in the mechanism by which polycyclic aromatic hydrocarbons (PAHs) cause mutations leading to the induction of cancer in the target organs (62) . The exposure of cells to 2.5 mM SA results in a significant inhibition of DMBA-DNA adduct formation that reaches a maximum value at 3.0 mM, a concentration compatible with drug plasma levels measurable during treatment of chronic inflammatory diseases (63, 64) . This effect may contribute to the aspirin breast cancer chemopreventive action observed in clinical trials and epidemiological and experimental studies; it also indicates that this drug can act in the first stage of carcinogenesis. As mentioned above, DMBA, in common with other PAHs, requires metabolic activation by CYPdependent monooxygenases, mainly CYP1A isoforms, or other oxidases before it can induce malignant transformation. As reported in the literature, prior exposure of MCF-7 cells to CYP inducers, such as PAHs or ß-NF, enhances CYP1A1 expression (47) (48) (49) . In our experiments, CYP1A was markedly induced by ß-NF and less by DMBA. Since both chemicals share a common induction mechanism, we evaluated the effects of SA on CYP1A1/1A2 expression in cells exposed to ß-NF. As detected by Western blotting, microsomes from ß-NFtreated MCF-7 cells showed a significant decrease in this protein after SA exposure. In contrast, we did not observe constitutive or inducible CYP1A1/1A2 protein in RMTCs. Both the expression and induction of this enzyme have been well documented in rat mammary glands (65) but, to the best of our knowledge, there is no study on CYP1A1 expression in DMBA-induced mammary tumours. Indeed, there are extensive studies on CYP expression in chemically-induced rat/mouse liver tumours revealing a decrease of the expression of this enzyme in hepatic tumours compared with adjacent non-neoplastic tissue (66) (67) (68) (70) reported that ibuprofen was able to inhibit COX-1 and COX-2 gene expression in DMBA-induced rat mammary tumours. Even so, we can assume that SA inhibits COX-1 activity in BCCs by a well-known mechanism, i.e. rapid reversible binding followed by covalent modification (acetylation) of Ser 530 of COX-1 (71) . Although the exact mechanism by which SA inhibits DMBA-DNA adduct formation in BCCs remains to be established, according to our results this effect may be due to SA's ability to decrease the expression of the enzymes involved in carcinogen bioactivation. Since several reports suggest inhibiton of tumour cell growth and induction of apoptosis as two possible explanations for the anti-tumour effects of NSAIDs (72), we have also investigated the effects of SA on BCC proliferation and viability in vitro. In line with the results of previous investigations (21, 28, 73) , SA proved effective in the inhibition of BCC growth but failed to cause cell death by necrosis or apoptosis. The latter finding is in contrast with previous reports on NSAID-induced apoptosis in breast cancer cells but agrees with the results of Din et al (69) , who showed that aspirin had no effect on viability and apoptosis in breast cancer cell lines. These differences may be explained by considering that induction of apoptosis was observed in studies using NSAIDs other than aspirin (20, 23, 74, 75) , while SA-induced apoptosis was observed only after long exposures (48-96 h) to high concentrations of drug beyond the therapeutic range (73) .
In conclusion, the present study demonstrates that SA significantly inhibits cell proliferation and DMBA-DNA adduct formation in the two tested types of BCC at concentrations which do not affect cell viability. The latter effect is possibly mediated via modulation of the expression of the enzymes involved in carcinogen bioactivation (CYP1A1/1A2 and COX), even if it is not possible to exclude other mechanisms, such as the induction of phase II detoxifying enzymes. Inhibition of adduct formation by SA represents a further mechanism responsible for aspirin chemopreventive efficacy that can be added to the several antitumour actions previously documented for NSAIDs. In our opinion, the antitumour effect exerted by SA and related agents is probably due to different actions of the drugs, strictly correlated in many cases, that collectively contribute to the final effect.
